X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (76) 76
Patent (10) 10
Book Chapter (4) 4
Book Review (4) 4
Book / eBook (2) 2
Conference Proceeding (1) 1
Publication (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (44) 44
pharmacology & pharmacy (34) 34
index medicus (28) 28
pharmacokinetics (23) 23
models, biological (21) 21
animals (19) 19
male (16) 16
adult (14) 14
oncology (14) 14
female (12) 12
middle aged (12) 12
antineoplastic agents - pharmacology (11) 11
dose-response relationship, drug (11) 11
aged (10) 10
calculating (10) 10
computing (10) 10
counting (10) 10
electric digital data processing (10) 10
healthcare informatics, i.e. information and communicationtechnology [ict] specially adapted for the handling orprocessing of medical or healthcare data (10) 10
information and communication technology [ict] specially adaptedfor specific application fields (10) 10
neoplasms - drug therapy (10) 10
pharmacology/toxicology (10) 10
physics (10) 10
analysis (9) 9
computer simulation (9) 9
models (9) 9
pharmacology (9) 9
antineoplastic agents - pharmacokinetics (8) 8
drug development (8) 8
antineoplastic agents - administration & dosage (7) 7
area under curve (7) 7
efficacy (7) 7
medicine & public health (7) 7
mice (7) 7
biological availability (6) 6
cancer (6) 6
cell line, tumor (6) 6
healthy-volunteers (6) 6
pharmacodynamics (6) 6
population (6) 6
tumors (6) 6
administration, oral (5) 5
drug evaluation, preclinical - methods (5) 5
drugs (5) 5
hepatic impairment (5) 5
metabolism (5) 5
plasma (5) 5
studies (5) 5
toxicology (5) 5
adrenergic uptake inhibitors - pharmacokinetics (4) 4
biochemistry & molecular biology (4) 4
combination therapy (4) 4
control or regulating systems in general (4) 4
controlling (4) 4
cross-over studies (4) 4
double-blind method (4) 4
drug design (4) 4
drug discovery (4) 4
exposure (4) 4
functional elements of such systems (4) 4
half-life (4) 4
internal medicine (4) 4
investigating or analysing materials by determining theirchemical or physical properties (4) 4
measuring (4) 4
metabolic clearance rate (4) 4
monitoring or testing arrangements for such systems orelements (4) 4
morpholines - pharmacokinetics (4) 4
neoplasms - pathology (4) 4
nonmem (4) 4
rats (4) 4
regulating (4) 4
research (4) 4
stereoisomerism (4) 4
testing (4) 4
time factors (4) 4
tissue distribution (4) 4
tumor growth inhibition (4) 4
aged, 80 and over (3) 3
algorithms (3) 3
anti-allergic agents - pharmacokinetics (3) 3
antidepressants (3) 3
antidepressive agents - pharmacokinetics (3) 3
antineoplastic agents - therapeutic use (3) 3
biomedicine (3) 3
cancer research (3) 3
chemotherapy (3) 3
clearance (3) 3
clinical neurology (3) 3
clinical trials (3) 3
drug therapy (3) 3
engineering, biomedical (3) 3
exemestane (3) 3
food-drug interactions (3) 3
hypersensitivity - drug therapy (3) 3
hypersensitivity - metabolism (3) 3
in-vitro data (3) 3
infusion (3) 3
inhibition (3) 3
inhibitor (3) 3
leukemia (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2019, Volume 84, Issue 4, pp. 707 - 717
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2015, Volume 75, Issue 1, pp. 111 - 121
Ibrutinib is an oral Bruton’s tyrosine kinase inhibitor, recently approved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia... 
Nonlinear mixed effects model | Medicine & Public Health | ADME | Covariate analysis | Oncology | Cancer Research | Phase I–II | Pharmacology/Toxicology | Phase I-II | ONCOLOGY | THERAPEUTIC TARGET | PCI-32765 | BTK | PHARMACOLOGY & PHARMACY | Pyrazoles - therapeutic use | Pyrimidines - blood | Humans | Middle Aged | Half-Life | Biological Availability | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Intestinal Absorption | Dose-Response Relationship, Drug | Lymphoma, Mantle-Cell - blood | Pyrazoles - blood | Aged, 80 and over | Adult | Female | Leukemia, Lymphocytic, Chronic, B-Cell - blood | Antineoplastic Agents - pharmacokinetics | Pyrazoles - pharmacokinetics | Lymphoma, Mantle-Cell - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Pyrimidines - administration & dosage | Food-Drug Interactions | Lymphoma, Mantle-Cell - drug therapy | Protein Kinase Inhibitors - blood | Cross-Over Studies | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Models, Biological | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Cohort Studies | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Analysis | Leukemia | Phenols | Lymphomas | Models | Antacids
Journal Article
Expert Opinion on Drug Metabolism & Toxicology, ISSN 1742-5255, 12/2010, Volume 6, Issue 12, pp. 1599 - 1604
The Population Approach Group in Europe meeting is the annual meeting of a group of scientists interested in quantitative pharmacology approaches. This meeting... 
population approaches | WinBUGS | pharmacometrics | pharmacokinetics | pharmacokinetic-pharmacodynamic | modelling | NONMEM | SYMCYP
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2018, Volume 36, Issue 3, pp. 476 - 486
Journal Article
Drug Discovery Today: Technologies, ISSN 1740-6749, 09/2013, Volume 10, Issue 3, pp. e365 - e372
Xenograft models are commonly used in oncology drug development. Although there are discussions about their ability to generate meaningful data for the... 
Dose-Response Relationship, Drug | Xenograft Model Antitumor Assays | Animals | Models, Biological | Humans | Disease Models, Animal | Neoplasms - drug therapy | Models | Information management | Analysis | Tumors
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 08/2019, Volume 25, Issue 16, pp. 4888 - 4897
Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor. Patients and Methods: Patients age >= 18 years... 
MOLECULAR CHARACTERIZATION | DOSE-ESCALATION | ONCOLOGY | FGF RECEPTORS | SENSITIVITY | BLADDER | MUTATIONS | CANCER | GENETIC ALTERATIONS
Journal Article